Yu Jianhong, Ni Jianchao, Chen Xindong, Fang Yuanyuan, Fu Suna
Jianhong Yu, Department of Geriatric, Affiliated Hospital of Shaoxing University, 999 Zhongxing South Road, Shaoxing, Zhejiang Province 312000, P.R. China.
Jianchao Ni Department of Geriatric, Affiliated Hospital of Shaoxing University, 999 Zhongxing South Road, Shaoxing, Zhejiang Province 312000, P.R. China.
Pak J Med Sci. 2024 Aug;40(7):1338-1344. doi: 10.12669/pjms.40.7.9209.
To explore the clinical effect of various doses of Budesonide combined with Tiotropium bromide in the treatment of elderly patients with chronic obstructive pulmonary disease (COPD).
Clinical data of elderly patients with COPD, admitted to Affiliated Hospital of Shaoxing University from April 2021 to February 2023, were retrospectively analyzed. Based on the dosage of Budesonide combined with Tiotropium bromide, patients were divided into Low-dose group (Budesonide = 1mg), Medium-dose group (Budesonide = 2mg), and High-dose group (Budesonide = 3mg). All groups were matched for age, gender, course of disease, and BMI. Patients treated with Tiotropium bromide alone were assigned to the Control group. The clinical effect, pulmonary function index level, symptom improvement, inflammatory factor index level and adverse reactions in all groups were analyzed and compared.
A total of 88 patients were included in this study with 22 patients in each group. The total efficacy of Medium-dose (90.91%) and High-dose group (90.91%) was significantly higher than that of Low-dose group (63.64%) and the Control group (59.09%) (<0.05). After the treatment, levels of pulmonary function, symptom improvement and inflammatory factors in the High-dose and the Medium-dose groups were better than those in the Low-dose group and the Control group. Pulmonary function, symptom improvement and levels of inflammatory factors was significantly better in the Low-dose group compared to the Control group (<0.05).
Budesonide combined with tiotropium bromide is better than tiotropium bromide alone in the treatment of elderly patients with COPD. Compared with low (1mg) dosage, medium (2mg) and high (3mg) dosage of budesonide are more effective in improving lung function, alleviating symptoms, reducing inflammatory response,, and are not associated with increased rate of adverse reactions.
探讨不同剂量布地奈德联合噻托溴铵治疗老年慢性阻塞性肺疾病（COPD）患者的临床效果。
回顾性分析2021年4月至2023年2月绍兴文理学院附属医院收治的老年COPD患者的临床资料。根据布地奈德联合噻托溴铵的剂量，将患者分为低剂量组（布地奈德=1mg）、中剂量组（布地奈德=2mg）和高剂量组（布地奈德=3mg）。所有组在年龄、性别、病程和BMI方面进行匹配。单独使用噻托溴铵治疗的患者被分配到对照组。分析并比较所有组的临床效果、肺功能指标水平、症状改善情况、炎症因子指标水平和不良反应。
本研究共纳入88例患者，每组22例。中剂量组（90.91%）和高剂量组（90.91%）的总有效率显著高于低剂量组（63.64%）和对照组（59.09%）（<0.05）。治疗后，高剂量组和中剂量组的肺功能、症状改善和炎症因子水平优于低剂量组和对照组。低剂量组的肺功能、症状改善和炎症因子水平明显优于对照组（<0.05）。
布地奈德联合噻托溴铵治疗老年COPD患者优于单用噻托溴铵。与低剂量（1mg）相比，中剂量（布地奈德=2mg）和高剂量（布地奈德=3mg）布地奈德在改善肺功能、缓解症状、减轻炎症反应方面更有效，且与不良反应发生率增加无关。
